Latest Breaking News On - Targeted copper theranostics - Page 5 : comparemela.com

SYDNEY, June 28, 2023 /PRNewswire/ Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce the establishment of a Center of Excellence at the Idaho Accelerator Center (IAC), a research facility operated by Idaho State University (ISU), for Targeted Copper Theranostics (TCTs). The IAC is a unique research facility operated by ISU located in southeast Idaho, US. It is the result of the Nuclear Science Application Project, providing opportunities for scientists and engineers from the University, the private sector and the national laboratories to utilise specialised nuclear facilities. Clarity is establishing the Center of Excellence at the IAC to advance research and development (R&D) of TCTs close to a source of copper-67 (Cu-67 or 67Cu) production. This investment will enable Clarity to effici

New south walesUnited statesIdaho state universityAlan taylorMartin blairJon stonerPrnewswire clarity pharmaceuticalsClarity pharmaceuticalsLs skaggs college of pharmacyTechnology platformIdaho accelerator centerNuclear science applicationTargeted copper theranosticsNuclear science application projectExecutive chairmanVice president